Clinical Trial Update: Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines [Phase 3]

View source ↗

Summary

Phase 3 trial of rivaroxaban for thromboprophylaxis in patients with cancer and central venous lines has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Central Venous Catheter Thrombosis
• Upper Extremity Deep Vein Thrombosis

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis | Phase 3 | Status: COMPLETED | Results posted: 2024-07-05